Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by Rifampin-resistant, rpoB mutant Mycobacterium tuberculosis

Journal of Bacteriology

Volumn 194, Issue 23, 2012, Pages 6441-6452

  Bisson, Gregory P ^a,b   Mehaffy, Carolina ^c   Broeckling, Corey ^c   Prenni, Jessica ^c   Rifat, Dalin ^d   Lun, Desmond S ^e,f   Burgos, Marcos ^g   Weissman, Drew ^a   Petros C Karakousis, ^d   Dobosc, Karen ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Department of Ecosystem Science and Sustainability   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e The State University of New Jersey   (United States)

^f UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^g UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLOROFORM; COMPLEMENTARY DNA; ERYTHROMYCIN; GAMMA INTERFERON; GENOMIC DNA; LIPID; LIPOPOLYSACCHARIDE; METHANOL; NATURAL PRODUCT; PHTHIOCEROL DIMYCOCEROSATE; POLYKETIDE SYNTHASE; PROTEOME; RIFAMPICIN; UNCLASSIFIED DRUG;

ACTINOBACTERIA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM MUTANT; BIOSYNTHESIS; ENZYME ACTIVITY; GENE EXPRESSION; GENE SEQUENCE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPERON; PRIORITY JOURNAL; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RPOB GENE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BIOSYNTHETIC PATHWAYS; CELL LINE; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; LIPIDS; MACROPHAGES; METABOLOME; MICE; MICROBIAL SENSITIVITY TESTS; MUTANT PROTEINS; MYCOBACTERIUM TUBERCULOSIS; PROTEOME; RIFAMPIN; TUBERCULOSIS;

ACTINOBACTERIA; ACTINOBACTERIA (CLASS); MURINAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 84871057692     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.01013-12     Document Type: Article

References (79)

1. Ahmad Z, et al. 2009. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J. Infect. Dis. 200:1136-1143.
2. Astarie-Dequeker C, et al. 2009. Phthiocerol dimycocerosates of M. tuberculosis participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids. PLoS Pathog. 5:e1000289. doi:10.1371/journal.ppat.1000289.
3. Azad AK, Sirakova TD, Fernandes ND, Kolattukudy PE. 1997. Gene knockout reveals a novel gene cluster for the synthesis of a class of cell wall lipids unique to pathogenic mycobacteria. J. Biol. Chem. 272:16741-16745.
4. Barnes PF, et al. 1989. Characterization of T cell antigens associated with the cell wall protein-peptidoglycan complex of Mycobacterium tuberculosis. J. Immunol. 143:2656-2662.
5. Bergval IL, Klatser PR, Schuitema AR, Oskam L, Anthony RM. 2007. Specific mutations in the Mycobacterium tuberculosis rpoB gene are associated with increased dnaE2 expression. FEMS Microbiol. Lett. 275:338-343.
6. Blanchard JS. 1996. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu. Rev. Biochem. 65:215-239.
7. Boshoff HI, et al. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279:40174-40184.
8. Braibant M, Gilot P, Content J. 2000. The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol. Rev. 24:449-467.
9. Brennan PJ. 2003. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb.) 83:91-97.
10. Camacho LR, et al. 2001. Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J. Biol. Chem. 276:19845-19854.
11. Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C. 1999. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol. Microbiol. 34:257-267.
12. Campbell EA, et al. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912.
13. Carata E, et al. 2009. Phenotypes and gene expression profiles of Saccharopolyspora erythraea rifampicin-resistant (rif) mutants affected in erythromycin production. Microb. Cell Fact. 8:18.
14. Carvalho PC, Hewel J, Barbosa VC, Yates JR III. 2008. Identifying differences in protein expression levels by spectral counting and feature selection. Genet. Mol. Res. 7:342-356.
15. Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A. 2002. Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J. Clin. Microbiol. 40:4435-4438.
16. Cole ST. 2005. Tuberculosis and the tubercle bacillus. ASM Press, Washington, DC.
17. Cole ST, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
18. Comas I, et al. 2011. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44:106-110.
19. Cox JS, Chen B, McNeil M, Jacobs WR, Jr. 1999. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402:79-83.
20. Daffe M, Laneelle MA. 1988. Distribution of phthiocerol diester, phenolic mycosides and related compounds in mycobacteria. J. Gen. Microbiol. 134:2049-2055.
21. Domenech P, Reed MB. 2009. Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from Mycobacterium tuberculosis grown in vitro: implications for virulence studies. Microbiology 155:3532-3543.
22. Dreger M. 2003. Subcellular proteomics. Mass Spectrom. Rev. 22:27-56.
23. Fu X, et al. 2008. Spectral index for assessment of differential protein expression in shotgun proteomics. J. Proteome Res. 7:845-854.
24. Gagneux S. 2009. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 15(Suppl. 1):66-68.
25. Gagneux S, et al. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-1946.
26. Gandhi NR, et al. 2010. Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830-1843.
27. Geffen N. 2010. Cepheid Gene Xpert diagnostic technology for TB. Memories of the 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease 3-7 December 2009. HIV Treatment Bulletin South (HTB), April 2010 (http://i-base.info/htb-south/960).
28. Gokhale RS, Saxena P, Chopra T, Mohanty D. 2007. Versatile polyketide enzymatic machinery for the biosynthesis of complex mycobacterial lipids. Nat. Prod. Rep. 24:267-277.
29. Golby P, et al. 2007. Comparative transcriptomics reveals key gene expression differences between the human and bovine pathogens of the Mycobacterium tuberculosis complex. Microbiology 153:3323-3336.
30. Gupta AK, et al. 2010. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb. Drug Resist. 16:21-28.
31. Haas WH, et al. 1997. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob. Agents Chemother. 41:1601-1603.
32. Herrera L, Jimenez S, Valverde A, Garcia-Aranda MA, Saez-Nieto JA. 2003. Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature. Int. J. Antimicrob. Agents 21:403-408.
33. Horai H, et al. 2010. MassBank: a public repository for sharing mass spectral data for life sciences. J. Mass Spectrom. 45:703-714.
34. Hosaka T, et al. 2009. Antibacterial discovery in actinomycetes strains with mutations in RNA polymerase or ribosomal protein S12. Nat. Biotechnol. 27:462-464.
35. Hu H, Zhang Q, Ochi K. 2002. Activation of antibiotic biosynthesis by specified mutations in the rpoB gene (encoding the RNA polymerase beta subunit) of Streptomyces lividans. J. Bacteriol. 184:3984-3991.
36. Huber LA, Pfaller K, Vietor I. 2003. Organelle proteomics: implications for subcellular fractionation in proteomics. Circ. Res. 92:962-968.
37. Inaoka T, Takahashi K, Yada H, Yoshida M, Ochi K. 2004. RNA polymerase mutation activates the production of a dormant antibiotic 3,3=-neotrehalosadiamine via an autoinduction mechanism in Bacillus subtilis. J. Biol. Chem. 279:3885-3892.
38. Izumi H, et al. 2010. Diversity of Mycobacterium species from marine sponges and their sensitivity to antagonism by sponge-derived rifamycinsynthesizing actinobacterium in the genus Salinispora. FEMS Microbiol. Lett. 313:33-40.
39. Jain M, Cox JS. 2005. Interaction between polyketide synthase and transporter suggests coupled synthesis and export of virulence lipid in M. tuberculosis. PLoS Pathog. 1:e2. doi:10.1371/journal.ppat.0010002.
40. Jain M, et al. 2007. Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids via metabolic coupling. Proc. Natl. Acad. Sci. U. S. A. 104:5133-5138.
41. Jin DJ, Gross CA. 1988. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol.202:45-58.
42. Kall L, Storey JD, MacCoss MJ, Noble WS. 2008. Assigning significance to peptides identified by tandem mass spectrometry using decoy databases. J. Proteome Res. 7:29-34.
43. Karakousis PC, Williams EP, Bishai WR. 2008. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J. Antimicrob. Chemother. 61:323-331.
44. Karakousis PC, et al. 2004. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J. Exp. Med. 200:647-657.
45. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. 2002. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74:5383-5392.
46. Kirksey MA, et al. 2011. Spontaneous phthiocerol dimycocerosatedeficient variants of Mycobacterium tuberculosis are susceptible to gamma interferon-mediated immunity. Infect. Immun. 79:2829-2838.
47. Kondo E, Kanai K. 1976. A suggested role of a host-parasite lipid complex in mycobacterial infection. Jpn. J. Med. Sci. Biol. 29:199-210.
48. Lavollay M, et al. 2008. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L, Dtranspeptidation. J. Bacteriol. 190:4360-4366.
49. Li MH, Ung PM, Zajkowski J, Garneau-Tsodikova S, Sherman DH.2009. Automated genome mining for natural products. BMC Bioinformatics 10:185.
50. Lonnroth K, et al. 2010. Tuberculosis control and elimination-50: cure, care, and social development. Lancet 375:1814-1829.
51. Louw GE, et al. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J.Respir. Crit. Care Med. 184:269-276.
52. Mahapatra S, Scherman H, Brennan PJ, Crick DC. 2005. N glycosylation of the nucleotide precursors of peptidoglycan biosynthesis of Mycobacterium spp. is altered by drug treatment. J. Bacteriol. 187:2341-2347.
53. Manganelli R, Dubnau E, Tyagi S, Kramer FR, Smith I. 1999. Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis. Mol. Microbiol. 31:715-724.
54. Mani C, Selvakumar N, Narayanan S, Narayanan PR. 2001. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J. Clin. Microbiol. 39:2987-2990.
55. Mehaffy C, et al. 2010. Descriptive proteomic analysis shows protein variability between closely related clinical isolates of Mycobacterium tuberculosis. Proteomics 10:1966-1984.
56. Murry JP, Pandey AK, Sassetti CM, Rubin EJ. 2009. Phthiocerol dimycocerosate transport is required for resisting interferon-gammaindependent immunity. J. Infect. Dis. 200:774-782.
57. Parish T, Brown A. 2009. Mycobacterium: genomics and molecular biology. Caister Academic Press, Norfolk, United Kingdom.
58. Park HD, et al. 2003. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol. Microbiol. 48:833-843.
59. Reed MB, et al. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87.
60. Rouse DA, Li Z, Bai GH, Morris SL. 1995. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:2472-2477.
61. Rousseau C, et al. 2004. Production of phthiocerol dimycocerosates protects Mycobacterium tuberculosis from the cidal activity of reactive nitrogen intermediates produced by macrophages and modulates the early immune response to infection. Cell Microbiol. 6:277-287.
62. Rustad TR, Harrell MI, Liao R, Sherman DR. 2008. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One 3:e1502. doi:10.1371/journal.pone.0001502.
63. Sartain MJ, Slayden RA, Singh KK, Laal S, Belisle JT. 2006. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Mol. Cell. Proteomics 5:2102-2113.
64. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol.48:77-84.
65. Shah NS, et al. 2007. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13:380-387.
66. Smith CA, et al. 2005. METLIN: a metabolite mass spectral database. Ther. Drug Monit. 27:747-751.
67. Subramanian A, et al. 2005. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc.Natl. Acad. Sci. U. S. A. 102:15545-15550.
68. Takayama K, Wang L, David HL. 1972. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis.Antimicrob. Agents Chemother. 2:29-35.
69. Tala A, et al. 2009. Activation of dormant bacterial genes by Nonomuraea sp. strain ATCC 39727 mutant-type RNA polymerase. J. Bacteriol. 191: 805-814.
70. Telenti A, et al. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650.
71. Thayil SM, Morrison N, Schechter N, Rubin H, Karakousis PC. 2011. The role of the novel exopolyphosphatase MT0516 in Mycobacterium tuberculosis drug tolerance and persistence. PLoS One 6:e28076. doi:10.1371/journal.pone.0028076.
72. Trivedi OA, et al. 2005. Dissecting the mechanism and assembly of a complex virulence mycobacterial lipid. Mol. Cell 17:631-643.
73. Vitali B, et al. 2008. Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin. Int. J. Antimicrob. Agents 31:555-560.
74. Vizcaino JA, et al. 2010. The Proteomics Identifications database: 2010 update. Nucleic Acids Res. 38:D736-D742.
75. WHO. 2010. Global tuberculosis control 2010. World Health Organization, Geneva, Switzerland.
76. WHO. 2010. Multi-drug and extensively drug-resistant TB (M/XDR-TB):2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland.
77. Wright A, et al. 2009. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373:1861-1873.
78. Yue J, et al. 2003. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China. J. Clin. Microbiol. 41:2209-2212.
79. Zazopoulos E, et al. 2003. A genomics-guided approach for discovering and expressing cryptic metabolic pathways. Nat. Biotechnol. 21:187-190.